Infusion of expanded TIL targeting four neoantigens across HLA-B, -C and -DRB1 restrictions induced a complete response in a breast cancer patient refractory to chemotherapy, ongoing for >22 months [55]. This evidence concerns the gene HLA-DRB1 and breast carcinoma.